Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 142

Sort by

Sort Order Select

Journal Articles

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Frederick Lansigan, MD, Ian Barak, MS, Brandelyn Nicole Pitcher, MS, Sin-Ho Jung, PhD, Bruce Cheson, MD, Myron S. Czuczman, MD, Barbara W. Grant, MD, Peter Martin, MD, Eric D. Hsi, MD, Heiko Schoder, MD, Scott E. Smith, MD PhD, Nancy L Bartlett, MD, John P. Leonard, MD, Kristie Blum, MD

Blood (2016) 128 (22): 2953.

https://doi.org/10.1182/blood.V128.22.2953.2953

Published: 2016

Journal Articles

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Natalie M. Czuczman, Matthew J. Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E. Frys, Qiang Hu, Song Liu, Pavel Klener, Petra Vockova, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri

Blood (2016) 127 (9): 1128–1137.

https://doi.org/10.1182/blood-2015-04-640920

Published: 2016

Includes: Supplemental data

Journal Articles

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3997.

https://doi.org/10.1182/blood.V126.23.3997.3997

Published: 2015

Journal Articles

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Pallawi Torka, MD, Priyank P. Patel, MD, Wei Tan, Gregory Wilding, Seema A. Bhat, MD, Myron S. Czuczman, MD, Kelvin P. Lee, MD, George Deeb, MD, Vishala T. Neppalli, MD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3975.

https://doi.org/10.1182/blood.V126.23.3975.3975

Published: 2015

Journal Articles

Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)

Aliyah R Sohani, MD, Brandy Pitcher, MS, Amy Chadburn, MD, Jonathan W. Said, MD, Peter Martin, MD, Myron S. Czuczman, MD, Nancy L Bartlett, MD, Cara A. Rosenbaum, MD, John P. Leonard, MD, Bruce D. Cheson, MD, Eric D. Hsi, MD

Blood (2015) 126 (23): 334.

https://doi.org/10.1182/blood.V126.23.334.334

Published: 2015

Journal Articles

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Chaitra S. Ujjani, MD, Sin-Ho Jung, PhD, Brandelyn Pitcher, MS, Peter Martin, MD, Steven I. Park, MD, Kristie A. Blum, MD, Sonali M. Smith, MD, Myron S. Czuczman, MD, Matthew S. Davids, MD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 471.

https://doi.org/10.1182/blood.V126.23.471.471

Published: 2015

Journal Articles

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Qunling Zhang, MD PhD, Juan J Gu, PhD, Ye Guo, MD, Jacob Klos, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 4006.

https://doi.org/10.1182/blood.V126.23.4006.4006

Published: 2015

Journal Articles

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 4008.

https://doi.org/10.1182/blood.V126.23.4008.4008

Published: 2015

Journal Articles

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 2761.

https://doi.org/10.1182/blood.V126.23.2761.2761

Published: 2015

Journal Articles

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Kyle L. Runckel, BS, Cory Mavis, MSc, Joseph Skitzki, Juan J Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2015) 126 (23): 590.

https://doi.org/10.1182/blood.V126.23.590.590

Published: 2015

Journal Articles

The SMAC Mimetic Lcl-161 Augments the in Vitro and in Vivo anti-Tumor Activity of Rituximab and Chemotherapy in Rituximab Relapse/Refractory Lymphoma Models

Kyle L. Runckel, BS, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2014) 124 (21): 3110.

https://doi.org/10.1182/blood.V124.21.3110.3110

Published: 2014

Journal Articles

Intense Cytarabine-Based Chemo-Immunotherapy, Central Nervous System (CNS) Prophylaxis and Early High-Dose Chemotherapy and Autologous Stem Cell Support (HDC-ASCS) in First Remission Are Associated with an Improved Clinical Outcome in Double-Hit (DHL)/Triple-Hit (THL) Diffuse Large B-Cell Lymphoma (DLBCL)

Priyank P. Patel, MD, Pallawi Torka, MD, Vishala T. Neppalli, MD, George Deeb, MD, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, Seema A. Bhat, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2014) 124 (21): 3031.

https://doi.org/10.1182/blood.V124.21.3031.3031

Published: 2014

Journal Articles

Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone +/- Rituximab (CHOP+/-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone +/- Rituximab (CEpOP+/-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568

Kai Xue, MD, Juan J Gu, PhD, Qunling Zhang, MD, Xiaojian Liu, MD, Jiachen Wang, Jianfeng Luo, Francisco J. Hernandez-Ilizaliturri, MD, Stanley F. Fernandez, MD, Myron S. Czuczman, MD, Junning Cao, MD Associate Professor, Xiaonan Hong, MD, Ye Guo, MD

Blood (2014) 124 (21): 3041.

https://doi.org/10.1182/blood.V124.21.3041.3041

Published: 2014

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

Kai Xue, MD, Juan Gu, PhD, Cory Mavis, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD, Ye Guo, MD

Blood (2014) 124 (21): 5486.

https://doi.org/10.1182/blood.V124.21.5486.5486

Published: 2014

Journal Articles

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

Myron S. Czuczman, MD, Andrew Davies, BM PhD, Kim M Linton, MBChB, MRCP, PhD, Nina Wagner-Johnston, Randy D. Gascoyne, MD, David A. Eberhard, MD PhD, Gilles Salles, MDPhD, Thomas E. Witzig, MD, Pier Luigi Zinzani, MD, PhD, George W. Wright, PhD, Louis M. Staudt, MD PhD, Jacqueline Repici, Dale Song, Oliver Manzke, MD, Ian D Lewis, MBBS, PhD

Blood (2014) 124 (21): 628.

https://doi.org/10.1182/blood.V124.21.628.628

Published: 2014

Journal Articles

Up-Regulation of Hexokinase II (HK) Alters the Glucose Metabolism and Disrupts the Mitochondrial Potential in Aggressive B-Cell Lymphoma Contributing to Rituximab-Chemotherapy Resistance and Is a Clinically Relevant Target for Future Therapeutic Development

Juan J Gu, PhD, Anil Singh, MD, Cory Mavis, MSc, Vivek Yanamadala, Kai Xue, MD, Michael Grau, Peter Lenz, Georg Lenz, Myron S. Czuczman, MD, Francisco Hernandez, MD

Blood (2014) 124 (21): 1767.

https://doi.org/10.1182/blood.V124.21.1767.1767

Published: 2014

Journal Articles

Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib

Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Sarah Belliotti, B.A., Cory Mavis, MSc, Juan Gu, PhD, Myron S. Czuczman, MD

Blood (2014) 124 (21): 1768.

https://doi.org/10.1182/blood.V124.21.1768.1768

Published: 2014

Journal Articles

Metformin Affects the Proliferation Cell Nuclear Antigen (PCNA) and p21 Protein Interaction Resulting in Direct Anti-Tumor Activity and Enhances the Cytotoxic/Biological Effects of Chemotherapy Agents or Rituximab in Lymphoma in Vitro and in Vivo Pre-Clinical Models

Juan J Gu, PhD, Vivek Yanamadala, Anil Singh, MD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco Hernandez, MD

Blood (2014) 124 (21): 1781.

https://doi.org/10.1182/blood.V124.21.1781.1781

Published: 2014

Journal Articles

Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup

Myron S. Czuczman, MD, Andre Goy, MD, Dominick Lamonica, MD, Daniel A. Graf, MD MPH, Mihaela C. Munteanu, MS, Richard H. van der Jagt, MD FRCP(C)

Blood (2014) 124 (21): 1757.

https://doi.org/10.1182/blood.V124.21.1757.1757

Published: 2014

NARROW

Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance)

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Augmenting Neutrophil Function By Administration of Peg-Filgrastim Potentiates Rituximab and Is Safe in Patients with Indolent B-Cell Non-Hodgkin Lymphomas: Results of a Phase II Study

Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401)

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

The SMAC Mimetic Lcl-161 Augments the in Vitro and in Vivo anti-Tumor Activity of Rituximab and Chemotherapy in Rituximab Relapse/Refractory Lymphoma Models

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

Up-Regulation of Hexokinase II (HK) Alters the Glucose Metabolism and Disrupts the Mitochondrial Potential in Aggressive B-Cell Lymphoma Contributing to Rituximab-Chemotherapy Resistance and Is a Clinically Relevant Target for Future Therapeutic Development

Inhibition of Nuclear Factor Kappa B (NFkB)/Interferon Regulatory Factor 4 (IRF4) Signaling Pathway in Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) By Combining MLN4924, a Novel NEDD8 Activating Enzyme Inhibitor (NAE) and Ibrutinib

Metformin Affects the Proliferation Cell Nuclear Antigen (PCNA) and p21 Protein Interaction Resulting in Direct Anti-Tumor Activity and Enhances the Cytotoxic/Biological Effects of Chemotherapy Agents or Rituximab in Lymphoma in Vitro and in Vivo Pre-Clinical Models

Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only